EIF4A3-induced hsa_circ_0078136 inhibits the tumorigenesis of retinoblastoma via IL-17 signaling pathway
- PMID: 39180619
- DOI: 10.1007/s10792-024-03276-6
EIF4A3-induced hsa_circ_0078136 inhibits the tumorigenesis of retinoblastoma via IL-17 signaling pathway
Abstract
Purpose: Retinoblastoma (RB) is one of the most common intraocular cancers, with the highest prevalence among infants and young children under the age five. Numerous findings across the literature illustrate the involvement and significance of circular RNAs (circRNAs) in human malignancies, including RB. The current investigation attempted to decipher the exact roles and underlying mechanisms of a novel circRNA, hsa_circ_0078136, in RB progression.
Methods: The hsa_circ_0078136 expression was evaluated in RB tumors and cell lines via qRT-PCR. The significance of hsa_circ_0078136 in RB was examined by performing CCK8 assay, transwell assays, western blotting of apoptotic and IL-17 signaling ligand molecules, and a subcutaneous xenograft tumor model. In addition, the interaction of circRNA and eukaryotic translation initiation factor 4A3 (EIF4A3) was determined with bioinformatics, western blot, and RIP assay.
Results: The hsa_circ_0078136 expression was reduced in RB tumor samples and cells. Additionally, its overexpression restricted the oncogenic properties of RB cells in vitro. Moreover, hsa_circ_0078136 overexpression lowered the protein levels of cytokine ligand molecules of IL-17 signaling pathway in RB cell lines. In vivo, hsa_circ_0078136 overexpression in subcutaneous tumor xenografts reduced tumor growth. We also observed that EIF4A3 binds to the downstream flanking sequence of hsa_circ_0078136 in the SHRPH pre-mRNA transcript, and EIF4A3 overexpression reduced hsa_circ_0078136 expression, suggesting that EIF4A3 inhibited hsa_circ_0078136 formation.
Conclusions: Our results demonstrate that hsa_circ_0078136 is regulated by EIF4A3 and functions as a tumor suppressor via the IL-17 signaling pathway in RB.
Keywords: EIF4A3; Hsa_circ_0078136; IL-17 signaling pathway; Retinoblastoma.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
References
-
- Mendonca V, Pereira Sena P, Evangelista Dos Santos AC, Rodrigues Bonvicino C, Ashton-Prolla P, Epelman S et al (2022) Diverse mutational spectrum in the 13q14 chromosomal region in a Brazilian cohort of retinoblastoma. Exp Eye Res 224:109211. https://doi.org/10.1016/j.exer.2022.109211 - DOI - PubMed
-
- Global Retinoblastoma Study G, Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S et al (2020) Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 6:685–695. https://doi.org/10.1001/jamaoncol.2019.6716 - DOI
-
- Cruz-Galvez CC, Ordaz-Favila JC, Villar-Calvo VM, Cancino-Marentes ME, Bosch-Canto V (2022) Retinoblastoma: review and new insights. Front Oncol 12:963780. https://doi.org/10.3389/fonc.2022.963780 - DOI - PubMed - PMC
-
- Li N, Wang YZ, Huang DS, Zhang Y, Zhang WL, Ma JM et al (2022) Clinical analysis of 16 distant metastatic retinoblastoma cases with event-free survival. Cancer Manag Res 14:367–375. https://doi.org/10.2147/CMAR.S349035 - DOI - PubMed - PMC
-
- Shields CL, Fulco EM, Arias JD, Alarcon C, Pellegrini M, Rishi P et al (2013) Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond) 27:253–264. https://doi.org/10.1038/eye.2012.175 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
